Top 10 Biologics CDMOs Expanded Capacity and Capabilities in 2023

Market research firm Roots Analysis has identified ten leading biologics contract development and manufacturing organizations (CDMOs) that expanded their capacity and capabilities during 2023. These strategic expansions are in response to the increasing demand for biologics and anticipated market growth.

Biologic drugs have become a rapidly growing segment of the pharmaceutical industry, offering novel treatments for various diseases, including cancer and rare disorders. However, their development and manufacturing are complex and costly, leading many biopharmaceutical developers to outsource production to specialized contract service providers. This trend has driven substantial growth in the biologics contract manufacturing market.

The report analyzed over 305 industry players. The selection of the top ten CDMOs was based on their service portfolio and capabilities. Companies that undertook expansions in 2023 include AGC Biologics, Catalent Biologics, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung BioLogics, Sandoz, Vetter Pharma, and WuXi Biologics.

Roots Analysis's study covers the biologics contract manufacturing market and its future opportunities through 2035. The demand for manufacturing services related to cell and gene therapies, such as plasmid DNA and viral vector production, has seen significant increases.